We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Elicio Therapeutics has reported promising findings from preclinical studies of ELI-005, a protein subunit, lymph node targeting Covid-19 vaccine candidate.